(EMAILWIRE.COM, July 18, 2019 ) According the latest research report "Cell Counting Market by Product (Instruments (Spectrophotometer, Cell Counter, Hemocytometer, Flow Cytometer, Hematology Analyzer), Consumables (Reagent, Assay Kits, Microplate)), End User (Pharmaceutical, Hospital, Research) - Global Forecast to 2023"

The overall cell counting market is expected to grow from USD 8.29 billion in 2017 to USD 12.31 billion by 2023, at a CAGR of 6.8% from 2018 to 2023.

Download a FREE Pdf Brochuer @:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=157450728

Cell counting plays a vital role in cell analysis it helps identify the viability of cells and cell growth, and quantifies the number of live or dead cells in cell culture. The advantages of improved image analysis and the growing use of high-throughput Flow Cytometry and automated Hematology Analyzers are aiding the growth of the market.

The cell counting market is expanding with the emergence of new technologies and increasing applications areas. These instruments are being used in various research, clinical & diagnostic, and industrial applications. Many life science companies are under pressure to maintain their existing profit margins and improve them in the future while facing enormous pressure to cut prices. This has led to dramatic shifts in the business models of some manufacturers in this industry.

The base year considered for the study is 2017, and the forecast has been provided for the period between 2018 and 2023.

Get Sample Report with all Graphs & Charts related to it @:-https://www.marketsandmarkets.com/requestsampleNew.asp?id=157450728

The prominent players in the global cell counting market are Danaher Corporation (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), Merck (Germany), Bio-Rad Laboratories (US), GE Healthcare (US), PerkinElmer (US), Agilent Technologies (US), BioTek Instruments (US), Tecan Group (Switzerland), Roche Diagnostics (Switzerland), Sysmex Corporation (Japan), HORIBA, Ltd. (Japan), Abbott Laboratories (US), and Siemens Healthineers (Germany).

Major Market Developments
• In May 2018, Danaher Corporation launched the DxH 900 hematology analyzer, giving mid- to high-volume clinical laboratories the ability to perform complete blood count and white blood cell differential tests with minimal repeats.
• In April 2018, BioTek Instruments collaborated with Agilent Technologies to create a new integrated metabolic analysis and imaging platform by integrating Agilent Seahorse XFe96/XFe24 Analyzers with the BioTek Cytation 1 Cell Imaging Multi-Mode Reader to improve assay workflow.
• In February 2018, Merck invested USD 19.51 million (EUR 16.6 million) in its new manufacturing and distribution centre for the Life Science business located in Mumbai to be completed in 2019. This will strengthen the company's overall manufacturing and supply chain infrastructure.